Evaluation of adverse events of CDK4/6 inhibitors: a real-world study based on the FAERS database
Background and purpose: The development and approval of inhibitors of cyclin-dependent kinase 4/6 (CDK4/6) is an essential milestone in treating hormone receptor-positive metastatic breast cancer. The efficacy of these drugs is similar, but the adverse events (AE) are different, directly affecting t...
Wedi'i Gadw mewn:
| Prif Awdur: | |
|---|---|
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Editorial Office of China Oncology
2023-10-01
|
| Cyfres: | Zhongguo aizheng zazhi |
| Pynciau: | |
| Mynediad Ar-lein: | http://www.china-oncology.com/fileup/1007-3639/PDF/1698723436180-1489019076.pdf |
| Tagiau: |
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|